AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30063303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 30063303 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 122
Study 30063303 — intervention group
Group type: EXPERIMENTAL
Intervention: Light therapy
Number of subjects: 122
Study 30063303 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination group (Fluoxetine + Light therapy)
Number of subjects: 122
Study 28844192 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (2.5 mg twice daily) plus Aspirin (100 mg once daily)
Number of subjects: 27395
Study 28844192 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban (5 mg twice daily)
Number of subjects: 27395
Study 28844192 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (100 mg once daily)
Number of subjects: 27395
Study 26250486 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 μg as tablet for 6 weeks)
Number of subjects: 70
Study 24558759 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 5.0 mg/kg (group A)
Number of subjects: 60
Study 24558759 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 7.5 mg/kg (group B)
Number of subjects: 60
Study 24558759 — intervention group
Group type: COMPARATOR
Intervention: Saline (group C)
Number of subjects: 60
Study 21332932 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 30 mg/day
Number of subjects: 1207
Study 21332932 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg/day
Number of subjects: 1207
Study 21332932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1207
Study 19568990 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% dexamethasone (DEX group)
Number of subjects: 37
Study 19568990 — intervention group
Group type: COMPARATOR
Intervention: 1% rimexolone (RIMEX group)
Number of subjects: 37
Study 17100744 — intervention group
Group type: EXPERIMENTAL
Intervention: TiUnite implants
Number of subjects: 15
Study 17100744 — intervention group
Group type: COMPARATOR
Intervention: Turned implants
Number of subjects: 15
Study 15301100 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquefacient nitrogen cryotherapy with antibiotic eye drops and ointments
Number of subjects: 126
Study 15301100 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic eye drops and 2% yellow mercury oxide ointments (Control)
Number of subjects: 126
Study 11181670 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 6232
Study 9329359 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (OCT) treatment (150-600 micrograms/day for 3-6 months)
Number of subjects: 59
Study 9329359 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (OCT) treatment
Number of subjects: 59
Study 9329359 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (OCT) treatment with low carbohydrate intake
Number of subjects: 59
Study 9329359 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 59
Study 8201559 — intervention group
Group type: COMPARATOR
Intervention: Monofocal intraocular lens
Number of subjects: 80
Study 8201559 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal intraocular lens
Number of subjects: 80
Study 3987179 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxylamine alone (S)
Number of subjects: 2931
Study 3987179 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen alone (A)
Number of subjects: 2931
Study 3987179 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of doxylamine and acetaminophen (C)
Number of subjects: 2931
Study 3987179 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 2931
Study 30371904 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (1000 mg)
Number of subjects: 87
Study 30371904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 27467003 — intervention group
Group type: EXPERIMENTAL
Intervention: Black hood assisted colonoscopy (BHAC)
Number of subjects: 1076
Study 27467003 — intervention group
Group type: COMPARATOR
Intervention: Conventional colonoscopy (CC)
Number of subjects: 1076
Study 24247476 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon-like peptide-1 (1.5 pmol/kg/min) plus intensive insulin therapy
Number of subjects: 18
Study 24247476 — intervention group
Group type: COMPARATOR
Intervention: Normal saline plus intensive insulin therapy
Number of subjects: 18
Study 22607579 — intervention group
Group type: EXPERIMENTAL
Intervention: Netazepide 5 mg
Number of subjects: 32
Study 22607579 — intervention group
Group type: EXPERIMENTAL
Intervention: Netazepide 25 mg
Number of subjects: 32
Study 22607579 — intervention group
Group type: EXPERIMENTAL
Intervention: Netazepide 100 mg
Number of subjects: 32
Study 22607579 — intervention group
Group type: COMPARATOR
Intervention: Netazepide (0.5-100 mg)
Number of subjects: 32
Study 22607579 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg
Number of subjects: 32
Study 22607579 — intervention group
Group type: EXPERIMENTAL
Intervention: Netazepide
Number of subjects: 32
Study 20673995 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 32 mg plus bupropion 360 mg per day
Number of subjects: 1742
Study 20673995 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 16 mg plus bupropion 360 mg per day
Number of subjects: 1742
Study 20673995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1742
Study 18577032 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 0
Study 18577032 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study 18577032 — intervention group
Group type: COMPARATOR
Intervention: Pimecrolimus cream 1% and Vehicle
Number of subjects: 0
Study 17161977 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg body weight)
Number of subjects: 9
Study 17161977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 15316475 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji Ortho LC (resin-modified glass ionomer adhesive)
Number of subjects: 398
Study 15316475 — intervention group
Group type: COMPARATOR
Intervention: Light Bond (conventional resin adhesive)
Number of subjects: 398
Study 15316475 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji Ortho LC
Number of subjects: 398
Study 15316475 — intervention group
Group type: COMPARATOR
Intervention: Light Bond
Number of subjects: 398
Study 15316475 — intervention group
Group type: EXPERIMENTAL
Intervention: Both adhesives
Number of subjects: 398
Study 10847232 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0
Study 10847232 — intervention group
Group type: COMPARATOR
Intervention: Prazosin
Number of subjects: 0
Study 10847232 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine and Prazosin
Number of subjects: 0
Study 9084949 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis of lidocaine HCl 2% with epinephrine 1:100,000
Number of subjects: 51
Study 9084949 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 51
Study 1286487 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide
Number of subjects: 34
Study 1286487 — intervention group
Group type: COMPARATOR
Intervention: Glipizide
Number of subjects: 34
Study 1286487 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide and Glipizide
Number of subjects: 34
Study 3993436 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose CPAF tests including facial skin temperature measurements
Number of subjects: 133
Study 3993436 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin temperature measurement methods (delta T, %T, delta MTCI)
Number of subjects: 133
Study 31177999 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with 2-3 serves per week of fresh, lean pork (MedPork)
Number of subjects: 33
Study 31177999 — intervention group
Group type: COMPARATOR
Intervention: Low-fat control diet (LF)
Number of subjects: 33
Study 28814395 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole grain-rich (WG) diet for 6 weeks
Number of subjects: 80
Study 28814395 — intervention group
Group type: COMPARATOR
Intervention: Refined grain-based (RG) diet for 6 weeks
Number of subjects: 80
Study 25896121 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care (CC) intervention of pharmacotherapy and/or cognitive behavioral therapy
Number of subjects: 274
Study 25896121 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 274
Study 23726126 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiphasic injection protocol (protocol I) with 89 mL of Optiray 350
Number of subjects: 30
Study 23726126 — intervention group
Group type: COMPARATOR
Intervention: Test bolus injection protocol (protocol II) with a 10 mL test bolus of Optiray 350 followed by 40 mL of contrast medium
Number of subjects: 30
Study 21702325 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.454% stannous fluoride dentifrice
Number of subjects: 111
Study 21702325 — intervention group
Group type: COMPARATOR
Intervention: 0.76% sodium monofluorophosphate dentifrice (negative control)
Number of subjects: 111
Study 19485286 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyclosporin A 1%
Number of subjects: 76
Study 19485286 — intervention group
Group type: COMPARATOR
Intervention: No topical cyclosporin A
Number of subjects: 76
Study 17027425 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity(ER)
Number of subjects: 0
Study 17027425 — intervention group
Group type: EXPERIMENTAL
Intervention: Specificity(ER)
Number of subjects: 0
Study 17027425 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening tool reapplications
Number of subjects: 0
Study 12716952 — intervention group
Group type: EXPERIMENTAL
Intervention: Blind subjects
Number of subjects: 0
Study 12716952 — intervention group
Group type: COMPARATOR
Intervention: Sighted subjects
Number of subjects: 0
Study 11040714 — intervention group
Group type: EXPERIMENTAL
Intervention: Body-mind training (guided relaxation technique combined with meditative stretching)
Number of subjects: 8
Study 9297399 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis (DP)
Number of subjects: 6
Study 9297399 — intervention group
Group type: EXPERIMENTAL
Intervention: Exchange transfusion (ET) and hemodialysis (HD)
Number of subjects: 6
Study 9297399 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 6
Study 9297399 — intervention group
Group type: EXPERIMENTAL
Intervention: Exchange transfusion (ET) and peritoneal dialysis (DP)
Number of subjects: 6
Study 8451895 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g Cefoxitin
Number of subjects: 243
Study 8451895 — intervention group
Group type: COMPARATOR
Intervention: 1.5 g Cefuroxim
Number of subjects: 243
Study 3457904 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt test, cold pressor test, treadmill and isometric exercise by handgrip
Number of subjects: 10
Study 31299658 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine care and educational program (video show, pamphlet, in-person counseling)
Number of subjects: 199
Study 31299658 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 199
Study 28511288 — intervention group
Group type: COMPARATOR
Intervention: PRO‐TR (tele-health followup by rheumatologist)
Number of subjects: 294
Study 28511288 — intervention group
Group type: COMPARATOR
Intervention: PRO‐TN (tele-health followup by nurse)
Number of subjects: 294
Study 28511288 — intervention group
Group type: EXPERIMENTAL
Intervention: Control (conventional outpatient followup by physicians)
Number of subjects: 294
Study 26938954 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-treated group (surgery and orthodontic traction using the Guide rod appliance)
Number of subjects: 28
Study 26938954 — intervention group
Group type: COMPARATOR
Intervention: Later-treated group (surgery and orthodontic traction using the Guide rod appliance)
Number of subjects: 28
Study 25980148 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional endoscopic sinus surgery (FESS)
Number of subjects: 78
Study 23086696 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (800 mg/day to 1800 mg/day)
Number of subjects: 0
Study 20103314 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin (150 IU/kg)
Number of subjects: 42
Study 20103314 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose heparin (300 IU/kg)
Number of subjects: 42
Study 20103314 — intervention group
Group type: COMPARATOR
Intervention: Both heparin groups (low-dose and high-dose)
Number of subjects: 42
Study 18926127 — intervention group
Group type: EXPERIMENTAL
Intervention: Learner-centered nutrition education
Number of subjects: 155
Study 18926127 — intervention group
Group type: COMPARATOR
Intervention: Control lesson about resource management
Number of subjects: 155
Study 18926127 — intervention group
Group type: EXPERIMENTAL
Intervention: Learner-centered nutrition education for participants in the Special Supplemental Nutrition Program for Women, Infants, and Children
Number of subjects: 155
Study 18926127 — intervention group
Group type: EXPERIMENTAL
Intervention: Learner-centered nutrition education for food stamp recipients
Number of subjects: 155
Study 15961531 — intervention group
Group type: EXPERIMENTAL
Intervention: C12 (0.4 kcal/min)
Number of subjects: 13
Study 15961531 — intervention group
Group type: EXPERIMENTAL
Intervention: C12 (0.1 kcal/min)
Number of subjects: 13
Study 15961531 — intervention group
Group type: EXPERIMENTAL
Intervention: C12 (0.2 kcal/min)
Number of subjects: 13
Study 15961531 — intervention group
Group type: COMPARATOR
Intervention: Control (saline; rate 4 ml/min)
Number of subjects: 13
Study 12165184 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 106
Study 12165184 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 106
Study 9695210 — intervention group
Group type: EXPERIMENTAL
Intervention: piperacillin/tazobactam 4.5 g every 8 h i.v.
Number of subjects: 83
Study 9695210 — intervention group
Group type: COMPARATOR
Intervention: ceftazidime 2 g every 8 h plus amikacin 15 mg/kg i.v. per day
Number of subjects: 83
Study 7664601 — intervention group
Group type: EXPERIMENTAL
Intervention: 100mg sodium prasterone sulfate
Number of subjects: 120
Study 7664601 — intervention group
Group type: EXPERIMENTAL
Intervention: 200mg sodium prasterone sulfate
Number of subjects: 120
Study 7664601 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 2671218 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Bupivacaine 0.5 per cent solution
Number of subjects: 15
Study 2671218 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 15
Study 776539 — intervention group
Group type: EXPERIMENTAL
Intervention: tolmetin 1200 mg per day
Number of subjects: 24
Study 776539 — intervention group
Group type: EXPERIMENTAL
Intervention: tolmetin 1400 mg daily
Number of subjects: 24
Study 776539 — intervention group
Group type: COMPARATOR
Intervention: indomethacin 150 mg daily
Number of subjects: 24
Study 776539 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 31689951 — intervention group
Group type: EXPERIMENTAL
Intervention: L-isoleucine (0.3 g/kg·LBM-1)
Number of subjects: 12
Study 31689951 — intervention group
Group type: EXPERIMENTAL
Intervention: L-leucine (0.3 g/kg·LBM-1)
Number of subjects: 12
Study 31689951 — intervention group
Group type: EXPERIMENTAL
Intervention: Equal (1:1 g) of L-leucine + L-isoleucine (0.3 g/kg·LBM-1)
Number of subjects: 12
Study 31689951 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3.5 g inert stevia)
Number of subjects: 12
Study 27862713 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-promoting advertisements
Number of subjects: 204
Study 27862713 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-warning advertisements
Number of subjects: 204
Study 27862713 — intervention group
Group type: COMPARATOR
Intervention: Non-alcohol advertisements
Number of subjects: 204
Study 26041325 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency cervical cerclage (ECC) combined with progesterone
Number of subjects: 100
Study 26041325 — intervention group
Group type: COMPARATOR
Intervention: Progesterone alone
Number of subjects: 100
Study 24235245 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% propolis solution
Number of subjects: 0
Study 24235245 — intervention group
Group type: COMPARATOR
Intervention: Control (no propolis)
Number of subjects: 0
Study 24235245 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days storage
Number of subjects: 0
Study 24235245 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 days storage
Number of subjects: 0
Study 21756795 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue enwrapping cisplatin
Number of subjects: 20
Study 21756795 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (control)
Number of subjects: 20
Study 19567515 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human GH (rhGH)
Number of subjects: 7
Study 19567515 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human GH (rhGH) + acipimox
Number of subjects: 7
Study 19567515 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7
Study 19567515 — intervention group
Group type: EXPERIMENTAL
Intervention: acipimox
Number of subjects: 7
Study 16885888 — intervention group
Group type: EXPERIMENTAL
Intervention: Supranettes pads
Number of subjects: 20
Study 16885888 — intervention group
Group type: COMPARATOR
Intervention: Topical antiallergic treatment (membrane stabilizer or antihistamine)
Number of subjects: 20
Study 15491434 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tacrolimus plus salicylic acid
Number of subjects: 24
Study 15491434 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus salicylic acid
Number of subjects: 24
Study 11195308 — intervention group
Group type: EXPERIMENTAL
Intervention: Canonical patterns
Number of subjects: 0
Study 11195308 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex patterns broken down into small canonical patterns
Number of subjects: 0
Study 9760291 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (specific type not mentioned)
Number of subjects: 268
Study 9760291 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical and brain imaging characteristics
Number of subjects: 268
Study 9760291 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable analysis
Number of subjects: 268
Study 7826794 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 23
Study 7826794 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 23
Study 2898227 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracerebroventricular (ICV) cholinergic drug infusion (bethanechol chloride)
Number of subjects: 4
Study 2898227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 29102231 — intervention group
Group type: EXPERIMENTAL
Intervention: Musician's earplugs
Number of subjects: 0
Study 29102231 — intervention group
Group type: COMPARATOR
Intervention: No earplugs
Number of subjects: 0
Study 29428819 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification for Help-Seeking Stigma (CBM-HS)
Number of subjects: 32
Study 29428819 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation
Number of subjects: 32
Study 29428819 — intervention group
Group type: COMPARATOR
Intervention: Both groups (CBM-HS and Psychoeducation)
Number of subjects: 32
Study 27426441 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated Er:YAG laser
Number of subjects: 20
Study 27426441 — intervention group
Group type: COMPARATOR
Intervention: Fully ablative Er:YAG laser
Number of subjects: 20
Study 24035142 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervener-delivered brief intervention (IBI)
Number of subjects: 781
Study 24035142 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized brief intervention (CBI)
Number of subjects: 781
Study 24035142 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 781
Study 22512894 — intervention group
Group type: EXPERIMENTAL
Intervention: RTG/EZG 600 mg/day
Number of subjects: 0
Study 22512894 — intervention group
Group type: EXPERIMENTAL
Intervention: RTG/EZG 900 mg/day
Number of subjects: 0
Study 22512894 — intervention group
Group type: EXPERIMENTAL
Intervention: RTG/EZG 1200 mg/day
Number of subjects: 0
Study 22512894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19171853 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 1002
Study 19171853 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 1002
Study 17991911 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigil (monitoring system intervention)
Number of subjects: 0
Study 17991911 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched SCU without Vigil)
Number of subjects: 0
Study 15969668 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose peanut challenge
Number of subjects: 40
Study 15969668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11911553 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 400 mg once daily
Number of subjects: 372
Study 11911553 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg twice daily
Number of subjects: 372
Study 10546561 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid (ALA) at 30 mg/kg
Number of subjects: 35
Study 10546561 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid (ALA) at 50 mg/kg
Number of subjects: 35
Study 7768494 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation (EVL)
Number of subjects: 134
Study 7768494 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic variceal sclerotherapy (EVS)
Number of subjects: 134
Study 2283646 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine retard 10 mg twice daily
Number of subjects: 41
Study 2283646 — intervention group
Group type: COMPARATOR
Intervention: atenolol 50 mg once daily
Number of subjects: 41
Study 371396 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole (TMP/SMZ)
Number of subjects: 111
Study 371396 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TMP/SMZ)
Number of subjects: 111